Alpha-amylase variants and polynucleotides patent application
Summary
The USPTO has published a new patent application, US20260085261A1, from Novozymes A/S concerning alpha-amylase variants and related polynucleotides. The application details specific molecular constructs and their potential uses.
What changed
This document is a publication of a patent application (US20260085261A1) filed by Novozymes A/S. The application pertains to novel alpha-amylase variants, the polynucleotides encoding them, and methods of their use. It includes specific CPC classifications related to enzymes and detergents.
This publication does not impose new regulatory obligations on companies. However, it is relevant for entities operating in the biotechnology and pharmaceutical sectors, particularly those involved in enzyme development or detergent formulation, as it may indicate potential future patent protection and competitive landscape shifts.
Source document (simplified)
ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
Application US20260085261A1 Kind: A1 Mar 26, 2026
Assignee
NOVOZYMES A/S
Inventors
Carsten ANDERSEN, Chakshusmathi Ghadiyaram, Rajendra Kulothungan Sainathan, Padmavathi Balumuri, Padma Venkatachalam Iyer, Iben Damager, Astrid Munch, Sohel Dalal
Abstract
The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
CPC Classifications
C11D 3/386 C12N 9/2414 C12N 9/2417 C12Y 302/01001
Filing Date
2025-05-07
Application No.
19201864
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.